Angiotech to participate in UBS Global Life Sciences Conference
On Monday, September 24, 2007 at 8:30am ET, Dr. William Hunter, Presidentand Chief Executive Officer of Angiotech, will give a 25-minute presentation.
A link to the live audio webcast of Dr. Hunter's remarks will be availableto all interested parties on Angiotech's website at http://www.angiotech.com/in the Investors section. The webcast will also be archived and available forreplay until October 27, 2007.
Note on Forward Looking Statements:
Statements contained in this press release that are not based onhistorical fact, including without limitation statements containing the words"believes," "may," "plans," "will," "estimate," "continue," "anticipates,""intends," "expects" and similar expressions, constitute "forward-lookingstatements" within the meaning of the U.S. Private Securities LitigationReform Act of 1995 and constitute "forward-looking information" within themeaning of applicable Canadian securities laws. All such statements are madepursuant to the "safe harbor" provisions of applicable securities legislation.Forward-looking statements may involve, but are not limited to, comments withrespect to our objectives and priorities for 2007 and beyond, our strategiesor future actions, our targets, expectations for our financial condition andthe results of, or outlook for, our operations, research development andproduct and drug development. Such forward-looking statements involve knownand unknown risks, uncertainties and other factors that may cause the actualresults, events or developments to be materially different from any futureresults, events or developments expressed or implied by such forward-lookingstatements.
Many such risks, uncertainties and other factors are taken into account aspart of our assumptions underlying these forward-looking statements andinclude, among others, the following: general economic and businessconditions, both nationally and in the regions in which we operate; marketdemand; technological changes that could impact our existing products or ourability to develop and commercialize future products; competition; existinggovernmental regulations and changes in, or the failure to comply with,governmental regulations; adverse results or unexpected delays in drugdiscovery and clinical development processes; decisions, and the timing ofdecisions, made by health regulatory agencies regarding approval of ourtechnology and products; the requirement for substantial funding to conductresearch and development and to expand commercialization activities orconsummate acquisitions; and any other factors that may affect performance. Inaddition, our business is subject to certain operating risks that may causethe actual results expressed or implied by the forward-looking statements inthis report to differ materially from our actual results. These operatingrisks include: our ability to attract and retain qualified personnel; ourability to successfully complete preclinical and clinical development of ourproducts; changes in business strategy or development plans; our failure toobtain patent protection for discoveries; loss of patent protection resultingfrom third party challenges to our patents; commercialization limitationsimposed by patents owned or controlled by third parties; our ability to obtainrights to technology from licensors; liability for patent claims and otherclaims asserted against us; our ability to obtain and enforce timely patentand other intellectual property protection for our technology and products;the ability to enter into, and to maintain, corporate alliances relating tothe development and commercialization of our te
You May Also Like